---
title: "目前是否應該購買諾和諾德公司的股票？"
description: "這家陷入困境的製藥巨頭可能在 2026 年迎來大復甦"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/260792540.md"
published_at: "2025-10-12T15:08:07.000Z"
---

# 目前是否應該購買諾和諾德公司的股票？

> 這家陷入困境的製藥巨頭可能在 2026 年迎來大復甦

The fallen pharma giant could make a big comeback in 2026.

### Related Stocks

- [NVO.US - 諾和諾德公司](https://longbridge.com/zh-HK/quote/NVO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Savvy Advisors Inc. Purchases 22,138 Shares of Novo Nordisk A/S $NVO | Savvy Advisors Inc. increased its stake in Novo Nordisk A/S by 83.0% in Q3, acquiring 22,138 shares, bringing its total  | [Link](https://longbridge.com/zh-HK/news/275761183.md) |
| Novo Nordisk to Manufacture Wegovy in Ireland Facility | Novo Nordisk to Manufacture Wegovy in Ireland Facility | [Link](https://longbridge.com/zh-HK/news/275789396.md) |
| Novo Nordisk CFO Karsten Munk Knudsen Sells Shares Worth Over DKK 8.3 Million | Novo Nordisk A/S announced that CFO Karsten Munk Knudsen sold 26,246 shares for DKK 8.3 million at DKK 315.60 each and 3 | [Link](https://longbridge.com/zh-HK/news/275652909.md) |
| Novo Nordisk Gets European Commission Approval for Higher-Dose Wegovy Injectable | 09:25 AM EST, 02/17/2026 (MT Newswires) -- Novo Nordisk ( NVO ) said Tuesday the European Commission has approved a 7.2  | [Link](https://longbridge.com/zh-HK/news/276138110.md) |
| Assessing Novo Nordisk (CPSE:NOVO B) Valuation After Recent Share Price Pullback And Mixed Returns | Novo Nordisk (CPSE:NOVO B) has experienced mixed returns, with a recent 1.7% gain but a 17.6% decline over the past mont | [Link](https://longbridge.com/zh-HK/news/275941659.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。